Genetic Signatures
Genetic Signatures is an ASX-listed molecular diagnostics company that develops proprietary 3base™ PCR-based EasyScreen™ detection kits for infectious disease screening, serving hospital and pathology laboratories globally through direct sales and distribution partners.
- Company typePublic
- Founded2001
- HeadquartersSydney, Australia
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Genetic Signatures does
Genetic Signatures Ltd. is an ASX-listed (ASX:GSS) molecular diagnostics company founded in 2001 by Dr. Geoffrey Grigg and headquartered in Newtown, NSW, Australia. The company develops and commercializes real-time PCR-based infectious disease detection products under the EasyScreen™ brand, built on its proprietary 3base™ technology platform. This technology applies bisulphite conversion to microbial DNA to simplify four-base sequences to three bases (cytosine to thymine), raising sequence homology from 75% to 95% and reducing primer requirements (e.g., 48 to 3), which enables highly multiplexed pathogen detection. The portfolio spans FDA 510(k) cleared kits for gastrointestinal parasite detection (8 parasites in a single test with 99% clinical accuracy), respiratory pathogen panels, sexually transmitted infections, antimicrobial resistance screening (ESBL/CPO), meningitis, and tropical disease panels, plus Analyte Specific Reagents (ASRs) for research use. The GS1 automated workflow system performs sample extraction and PCR setup with 384-well capacity, complemented by GS-Call software for automated result interpretation and LIS/LIMS integration validated on the Bio-Rad CFX platform.
The company serves hospital and pathology laboratories globally, with reference customers including Blackpool Teaching Hospitals NHS Foundation Trust (UK), SydPath (Australia), ARUP Laboratories (US), and the New York State Department of Health Wadsworth Center. The commercial model combines direct enterprise sales in core markets (USA, EMEA, Australia) with regional distribution partnerships spanning Ireland, South Africa, UAE, Qatar, Saudi Arabia, Bahrain, Israel, Greece, and Italy. Revenue is generated primarily through consumable kit sales and GS1 instrument placements under multi-year contracts with quote-based pricing. The product architecture is a platform-plus-modules model: the 3base™ technology and EasyScreen Sample Processing Kit serve as universal inputs, with disease-area detection kits layered on top, generating recurring consumables revenue on top of one-time instrument sales.
H1 FY26 revenue was AUD 8.7 million (2.4% YoY growth) at a 55.7% gross margin (down from prior periods due to rising consumables costs), with an AUD 6.4 million operating loss. The company is currently undergoing a major operational reset: the share price is down 77% over the past year amid slower-than-expected US market penetration, the board initiated a forensic review and appointed advisors to assess commercialization strategy, restructuring was announced in March 2026 with up to 30 redundancies, the CFO resigned in November 2025, and the company is on its third CEO in two years (Melki → Rossiter → Halasz). The incoming CEO's stated focus is cost discipline and US revenue acceleration.
Genetic Signatures firmographics
Firmographics- Name
- Genetic Signatures
- Legal name
- Genetic Signatures Ltd.
- Website
- https://geneticsignatures.com
- Company type
- Public
- Founded year
- 2001
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Genetic Signatures is an ASX-listed molecular diagnostics company that develops proprietary 3base™ PCR-based EasyScreen™ detection kits for infectious disease screening, serving hospital and pathology laboratories globally through direct sales and distribution partners.
- Ownership category
- akta.pro rank
Genetic Signatures industry classification
Industry- Product category
- Molecular Diagnostics
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413), Analytical Laboratory Instrument Manufacturing (334516), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Molecular Diagnostics (PCR/NAAT/NGS-based IVD) (HLAHAAAD)
- akta.pro secondary industries
- Molecular Diagnostics (PCR/qPCR, NGS-based assays) (HLAAALAA), Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays) (HLAAALAL)
Keywords
Where Genetic Signatures is headquartered
LocationHeadquarters
- HQ city
- Sydney
- HQ country
- Australia
- HQ region
- Oceania
Offices4 records
Markets served
Genetic Signatures business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Supply Chain, Technology or R&D, Marketing or Sales, Operations
Revenue model
- EasyScreen Detection Kits: Sale of real-time PCR-based detection kits for infectious disease screening including gastrointestinal, respiratory, sexual health, antimicrobial resistance, meningitis, and tropical disease panels. Revenue from consumable reagents used in molecular diagnostics testing.
- GS1 Automated Systems: Sale of automated sample processing and PCR setup equipment. One-time hardware purchase with ongoing consumables revenue.
- Sample Processing Kits: Universal extraction kits for all sample types, sold as consumables. Revenue is recurring as laboratories require continuous supply for testing operations.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | B2B laboratory diagnostic products - no public pricing tiers |
Go-to-market motion3 records
Distribution channels5 records
Marketing channels8 records
Genetic Signatures product offering
Product offeringCore offering
Genetic Signatures develops and commercializes molecular diagnostic products based on its proprietary 3base™ technology for clinical laboratories. The company sells EasyScreen™ real-time PCR detection kits for infectious disease screening (gastrointestinal, respiratory, sexual health, antimicrobial resistance, meningitis, tropical diseases), along with the GS1 automated workflow system and Sample Processing Kits, targeting hospital and pathology laboratories globally.
Product overview
Genetic Signatures offers a platform-plus-modules product architecture centered on its proprietary 3base® technology. The core EasyScreen™ brand encompasses real-time PCR-based detection kits for infectious disease screening across multiple disease areas including gastrointestinal infections, respiratory pathogens, sexual health, antimicrobial resistance, meningitis, and tropical diseases. The portfolio includes the FDA 510(k) cleared EasyScreen™ Gastrointestinal Parasite Detection Kit (detecting 8 parasites in a single test) and the GS1 automated workflow system for sample extraction and PCR setup. The EasyScreen™ Sample Processing Kit serves as a universal input across all detection assays, while GS-Call software provides data analysis and LIS integration. Analyte Specific Reagents (ASRs) offer research-use-only customized detection options. The products range from cleared/IVD diagnostics to RUO reagents, serving clinical laboratories, hospitals, and research institutions.
Differentiator
Problem solved
Functional benefit
Brands
- EasyScreen™: Brand name for Genetic Signatures' suite of real-time PCR-based products for routine detection of infectious diseases, including detection kits for gastrointestinal infections, respiratory pathogens, sexual health, antimicrobial resistance, meningitis, and tropical diseases.
- 3base®
- MethylEasy™
- GS1
Products and services
- EasyScreen™ Gastrointestinal Parasite Detection Kit FDA 510(k) cleared multiplex PCR test that detects 8 gastrointestinal parasites in a single test from a single patient sample; for clinical laboratories replacing O&P microscopy methods.
- GS1 Automated Workflow System Automated platform performing both sample extraction and PCR setup with 384-well PCR setup capacity, wizard-driven interface for sample/reagent traceability, automated data analysis, and LIS integration. Processes up to 60 patients with same-day reporting.
- EasyScreen™ Sample Processing Kit Universal extraction kit that streamlines preparation of nucleic acids directly from primary specimens; isolates both DNA and RNA; compatible with all EasyScreen™ Pathogen Detection Reagents. Available in SP008B and SP012 sizes.
- GS-Call Software Automated calling software for easy interpretation of PCR results with LIS/LIMS integration, flexible target selection/deselection, and PDF report generation; validated on Bio-Rad CFX real-time PCR system.
- EasyScreen™ Respiratory Detection Kit Real-time PCR-based detection kit for routine identification of respiratory viruses, bacteria, and atypical pathogens; for clinical microbiology laboratories.
- EasyScreen™ SARS-CoV-2 Detection Kit Real-time PCR test for detection of SARS-CoV-2 virus; validated on saliva samples and demonstrating 100% match to Omicron variant by in silico analysis.
- EasyScreen™ ESBL/CPO Detection Kit Detection kit for Extended-Spectrum Beta-Lactamases (ESBL) and Carbapenemase-Producing Organisms (CPO) supporting antimicrobial resistance screening programs in clinical and hospital laboratories.
- EasyScreen™ Enteric Bacteria Detection Kit CE-IVD marked real-time PCR test for detection of enteric bacterial pathogens causing gastrointestinal infections; for European clinical laboratories.
- Analyte Specific Reagents (ASRs) Research use only reagents for respiratory, gastrointestinal, sexual health, antimicrobial resistance, tropical, and meningitis disease areas; allows laboratories to explore customized pathogen detection options using 3base™ technology.
- EasyScreen™ Sexual Health Detection Kit Real-time PCR-based detection kit for sexually transmitted infections and reproductive health pathogens; for clinical laboratories performing STI screening.
- EasyScreen™ Meningitis Detection Kit Real-time PCR-based detection kit for viral, bacterial, and fungal meningitis pathogens; for hospital and reference laboratories.
- EasyScreen™ Tropical Disease Detection Kit Real-time PCR-based detection kit for flavivirus and alphavirus screening in tropical disease applications; for clinical and reference laboratories.
Quantifiable outcome
- Detects 8 gastrointestinal parasites in single test with 99% overall accuracy (FDA 510(k) clinical studies)
- +3 more outcomes
Companies that use Genetic Signatures
Customer profileNamed customers4 records
Segments3 records
Ideal customer profiles2 records
Genetic Signatures technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration3 records
Feature4 records
Genetic Signatures partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core.
- Almog DiagnosticcoreStrategic channel partnership for market entry into Israel. Based in Shoham, Israel. Handles distribution and support of Genetic Signatures products in the Israeli market.
- Medical Supply Company Ltd.coreDistribution partner for Ireland and Northern Ireland. Located in Dublin, Republic of Ireland. Handles local sales and support of Genetic Signatures products in the Irish market.
- The Scientific GroupcoreDistribution partner for South Africa. Located in Vorna Valley, Roodepoort, South Africa. Handles local distribution and support of diagnostic products.
- Integrated Gulf Biosystems (IGB)coreStrategic partnership for Middle East market expansion. Dubai-based distributor covering UAE and regional markets including Qatar, Saudi Arabia, and Bahrain. Partners participated jointly in Global Health Exhibition 2023.
- SafeBlood BioAnalyticacoreDistribution partner for Greece. Located in Athens, Greece. Handles local sales and distribution of diagnostic products.
- Tema RicercacoreDistribution partner for Italy. Located in Castenaso (BO), Italy. Handles local distribution of molecular diagnostic products.
Scale indicators11 records
Recent moves7 records
Expansion highlights6 records
Genetic Signatures competitors and assessment
Company assessmentDirect peers
- Seegene: Seegene develops multiplex real-time PCR assays for syndromic infectious disease testing (respiratory, GI, STI, meningitis) under its Allplex brand. Seegene is a direct competitor to Genetic Signatures' EasyScreen multiplex kits in global hospital laboratory markets.
- BioFire Diagnostics (bioMérieux): BioFire's FilmArray panels are the leading multiplex syndromic PCR panels for respiratory, GI, meningitis/encephalitis, and bloodstream infections. They are the closest direct competitor to Genetic Signatures' EasyScreen multiplex kits, sharing the same hospital-laboratory customer base and syndromic testing model.
Broad incumbents
- Abbott Molecular: Abbott's m2000 and Alinity m systems deliver high-throughput automated molecular diagnostics including infectious disease panels. Abbott is a broad incumbent competing with Genetic Signatures in hospital and reference laboratory placements globally.
- QIAGEN: QIAGEN supplies sample preparation kits, PCR assays, and automated workflows (QIAcube, QIAstat-Dx) used in molecular diagnostics laboratories globally. It overlaps with Genetic Signatures' Sample Processing Kits and EasyScreen workflows, particularly in infectious disease testing.
- Becton, Dickinson and Company (BD): BD's BD MAX System and BD Veritor offer automated molecular and rapid diagnostics for infectious diseases including GI and respiratory pathogens. BD competes with Genetic Signatures in hospital laboratories seeking integrated molecular workflows.
- Cepheid (Danaher): Cepheid's GeneXpert system is the dominant fully-automated PCR molecular diagnostics platform used in hospital and reference laboratories worldwide. It directly competes with Genetic Signatures' EasyScreen kits and GS1 workflow in syndromic infectious disease testing, though Cepheid operates at much greater scale across a broader menu.
- Hologic: Hologic's Panther system offers fully-automated, high-throughput molecular testing with a broad menu in women's health and infectious diseases. It competes with Genetic Signatures for hospital and reference laboratory placements where automation and menu breadth matter.
- DiaSorin (Luminex): DiaSorin acquired Luminex, whose NxTAG and ARIES platforms offer multiplex molecular testing for respiratory, GI, and other infectious disease targets. DiaSorin competes with Genetic Signatures in hospital laboratories seeking syndromic multiplex solutions.
- Roche Diagnostics: Roche's cobas Liat and cobas 6800/8800 systems deliver high-throughput molecular diagnostics for infectious diseases, including the cobas TV/MG and respiratory panels. Roche is the global market leader and a competitor for both routine infectious disease testing and syndromic panels.
Regional players
- AusDiagnostics: AusDiagnostics is an Australian-based molecular diagnostics company selling multiplexed automated PCR kits (TIGRES workflow) for infectious disease and other applications. It is headquartered in the same Australian market as Genetic Signatures and competes head-to-head in regional hospital laboratories.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Genetic Signatures social profiles
Digital presenceGenetic Signatures compliance and trust
Trust signalCompliance3 records
Genetic Signatures financial estimates
Financial estimateRevenue estimate
Valuation estimate
Genetic Signatures leadership team
Management profileNumber of profiles
Profiles7 records
Genetic Signatures funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Genetic Signatures M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Genetic Signatures
What does Genetic Signatures do?
Genetic Signatures develops and commercializes molecular diagnostic products based on its proprietary 3base™ technology for clinical laboratories. The company sells EasyScreen™ real-time PCR detection kits for infectious disease screening (gastrointestinal, respiratory, sexual health, antimicrobial resistance, meningitis, tropical diseases), along with the GS1 automated workflow system and Sample Processing Kits, targeting hospital and pathology laboratories globally.
Is Genetic Signatures a public or private company?
Genetic Signatures is a public company. It is classified as public and is currently operating.
When was Genetic Signatures founded?
Genetic Signatures was founded in 2001. It employs 51 to 100 people.
Where is Genetic Signatures based?
Genetic Signatures is headquartered in Sydney, Australia, in the Oceania region.
How does Genetic Signatures make money?
Three revenue lines are on record. EasyScreen Detection Kits are the primary driver. The others are GS1 Automated Systems and sample Processing Kits.
Who are Genetic Signatures's main competitors?
Direct peers on record are Seegene and BioFire Diagnostics (bioMérieux). Broad incumbents are Abbott Molecular, QIAGEN, Becton, Dickinson and Company (BD), Cepheid (Danaher), Hologic, DiaSorin (Luminex) and Roche Diagnostics. AusDiagnostics is listed as a regional player.
Does Genetic Signatures have an API?
No public API is recorded for Genetic Signatures.
What industry is Genetic Signatures in?
Genetic Signatures's product category is Molecular Diagnostics. Its primary akta.pro industry code is HLAHAAAD, Molecular Diagnostics (PCR/NAAT/NGS-based IVD), with a secondary code of HLAAALAA, Molecular Diagnostics (PCR/qPCR, NGS-based assays). Its NAICS code is 325413 and its SIC code is 2835.